| | Latest News | Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity |
|
| Catalent announced its plans to acquire Metrics Contract Services (Metrics), a full-service specialty CDMO with a facility in Greenville, North Carolina, from Mayne Pharma Group Ltd. Upon completion, the acquisition will expand Catalent’s capacity to handle highly potent compounds while also strengthening its oral solid formulation development, manufacturing, and packaging capabilities. |
|
| The 333,000 square-foot Greenville facility features comprehensive capabilities and a one-site solution to accelerate and de-risk customer programs from early development through to commercial launch. |
|
| | | Xenetic Biosciences Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study |
|
| Xenetic Biosciences, Inc., a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers, recently announced it had entered into a manufacturing agreement with Catalent that will include CGMP manufacturing for the Company's recombinant protein, Human DNase I. "This agreement is |
|
| an important step towards long-term collaboration between Catalent and Xenetic," commented Vikalp Mohan, Global Vice President, Head of Drug Substance at Catalent Biologics. "We look forward to leveraging Catalent's proven biomanufacturing expertise at our site in Madison, Wisconsin, to support the advancement of Xenetic's DNase clinical development program and accelerating their path to first-in-human studies."
| | Read More |
|
| | | Fierce Pharma: Catalent has a new CEO plus a revamped operating structure |
|
| The shift comes just days after the company’s new chief executive Alessandro Maselli took the reins from longtime CEO John Chiminski, who’s pivoted to executive chair of the manufacturer’s board of directors. Now, rather than reporting on the performance of four different business segments, the new Maselli-led Catalent will focus on the two areas above—biologics, plus pharmaceuticals and consumer health—which each represent roughly half of the company’s total revenue. |
|
| | | American Pharmaceutical Review: Controlled Release Roundtable May 2022 |
|
| How has the pandemic and associated supply chain issues affected the development of controlled release products? In this roundtable discussion, Catalent’s Brent Moody, Director Science and Technology, talks about supply chain challenges and how Catalent has been able to mitigate some of the impact of the pandemic through a robust and well-established network of vendors. |
|
| | | Upcoming Events: Join Our Experts to Hear the Latest on Technology Development Programs |
|
| | | | | | | | | | | | | | | | | | | | | | | A Catalyst in Drug Development |
|
| Dejan Lamešić, Ph.D.
Head of Formulation and Process Development |
|
| Dr. Lamešić specializes in the material science of excipients, specifically fillers and polymers for immediate and controlled-release solid dosage forms. His expertise in particle engineering and the compaction process includes tableting and dry granulation. Discover what drives his passion for pharmaceutical materials science; read his published works, including peer-reviewed articles. |
|
| | |
|
Biologics
Video: “ Drug Substance Manufacturing” Explore Catalent’s biologics site in Bloomington, Indiana, that incorporates a drug substance manufacturing area including production bioreactors ranging up to 2,500L stainless steel and 2,000L single-use bioreactors |
|
| Pharmaceuticals and Consumer Health
Webinar: ‘Utilizing Phase-Appropriate CMC Strategies Throughout Clinical Development”
From both the regulatory and manufacturing perspective, phase-appropriate strategies can help focus available resources to efficiently achieve drug development goals and move to the next milestone. Learn how to accelerate and de-risk clinical-stage drug programs by understanding the strategies that can give your molecule the best chance for success.
Article: “Roles and Responsibilities of Specialized Clinical Supply Experts” Having a team of individuals with specialized expertise in different areas of clinical supply—from protocol review and early operational planning, to managing the development and execution of a sound clinical supply strategy—can prove invaluable to the overall suitability and performance of the supply chain, and in turn, the successful execution of the study itself. Learn more about the differences in areas of expertise, focus and responsibilities of the Clinical Supply Manager, the Project Manager, and the Financial Project Analyst.
Article: “ The Pandemic’s Impact on Over-the-Counter Cough and Cold Product Innovation” As the consumer health industry emerges from a slowdown in innovation due to the pandemic, Catalent Consumer Health keeps a close watch on the global market to identify key trends, innovation opportunities, and performance across categories. In this article, Catalent experts examine how the pandemic has impacted cough and cold product innovation, and what this means for the market.
Article: “ Innovations and the Impact of COVID-19” The increasing number of over-the-counter (OTC) pain medications is changing the analgesics market landscape. In this article, Catalent experts highlight how the COVID-19 pandemic and the increasing demands of ever more health and wellness-conscious consumers are driving innovation in OTC pain medications.
Article: “ New Entrants in Self Care” The recent decrease in mergers and acquisitions activity in the wellness, vitamins, minerals, and dietary supplements (VMS) space by multinational over-the-counter and pharmaceutical corporations has presented consumer-packaged goods (CPG) corporations and regional partners with more opportunities to expand the reach of their own businesses. |
|
| | | Biologics
In this 360° Virtual Tour, explore Catalent’s Houston clinical development and manufacturing facility for cell therapies. The state-of-the-art facility, at approximately 32,000 sq. ft., houses eight CGMP clean rooms, two tech transfer labs, and fill/finish services. The site has broad cell type expertise across immunotherapies and stem cells for both autologous and allogeneic cell therapy programs. | Pharmaceuticals and Consumer Health
In this 360° Virtual Tour, explore Catalent’s center of excellence for late phase and commercial-scale spray dry manufacturing in Haverhill, U.K. The site offers industry leading expertise in the scale-up and commercialization of spray dried dispersions as well as a broad range of integrated analytical support services. |
|
| We are the Catalyst for your success. Join us! |
|
| Catalent ignites the development of their future leaders by continuously investing in their employees and creating an innovative environment to advance their potential. We are growing rapidly across sites in Bloomington, Indiana; Madison, Wisconsin; Harmans, Maryland; Kansas City, Missouri; and elsewhere.
Visit www.catalent.com/careers for more information. |
|
| | |
|
Every molecule has a challenge. We have a solution.
|
|
| | | or call +1 877 891 9609 to speak with one of our experts today! |
|
| | |
|
To unsubscribe or manage your subscriptions, please click here.
For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at sales@catalent.com, or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers.
Catalent Pharma Solutions respects your privacy.
Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement of the website, its owner(s) or the content.
© 2022, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved.
|
|
|
|
|
